Drug Type Gene therapy  | 
Synonyms-  | 
Target  | 
Action modulators  | 
Mechanism UBE3A modulators(ubiquitin protein ligase E3A modulators), Gene expression modulators  | 
Therapeutic Areas  | 
Active Indication  | 
Inactive Indication-  | 
Originator Organization  | 
Active Organization  | 
Inactive Organization-  | 
License Organization-  | 
Drug Highest PhasePreclinical  | 
First Approval Date-  | 
Regulation-  | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Angelman Syndrome | Preclinical | United States   | 23 Apr 2024 | 





